GleamWall
中文EN

ACUT Accustem Sciences Inc.

Pharmaceutical Preparations · OTC · SEC CIK 1850767 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-7.2%
TTM EPS YoY8.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-102.7%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets356.4%
Debt / equity—
Current ratio0.02x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.73x
Accruals ratio-27.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-312024Q32024-09-30
Income statement
Revenue$98,400———————
R&D expense$43,712$119,525$119,744$72,720$60,204$28,346$41,972$31,409
SG&A expense$307,261$366,358$394,644$327,177$341,199$412,062$330,129$296,765
Operating income-$252,573-$485,883-$514,388-$399,897-$401,403-$440,408-$372,101-$328,174
Pretax income—-$485,883-$514,388-$399,897-$401,403-$440,408-$372,101-$328,174
Net income-$252,573-$485,883-$514,388-$399,897-$401,403-$440,408-$372,101-$328,174
EBITDA——-$514,388-$399,897-$401,298-$440,095-$371,194-$327,267
EPS (basic)-0.02-0.03—-0.02-0.02-0.03—-0.03
EPS (diluted)-0.02-0.03—-0.02-0.02-0.03—-0.03
Weighted avg. shares (diluted)16.07M16.07M—16.07M16.07M12.72M—11.35M
Balance sheet
Cash & equivalents$12,928$12,207$13,929$14,391$31,341$36,381$5,046$37,080
Current assets$106,204$49,532$49,446$1.57M$1.61M$1.55M$50,433$102,494
PP&E, net—————$105$418$1,325
Total assets$1.61M$1.55M$1.55M$1.57M$1.61M$1.55M$50,851$103,819
Current liabilities$5.72M$5.42M$4.95M$4.48M$4.15M$3.71M$3.36M$3.30M
Total liabilities$5.72M$5.42M$4.95M$4.48M$4.15M$3.71M$3.36M$3.30M
Shareholders' equity-$4.12M-$3.87M-$3.40M-$2.91M-$2.53M-$2.16M-$3.31M-$3.19M
Shares outstanding16.07M16.07M16.07M16.07M16.07M16.07M12.10M11.35M
Cash flow statement
Operating cash flow-$248,850-$374,176$22,357-$604,131$21,567-$290,182$414-$217,947
Financing cash flow$249,571$372,454-$22,820$587,181-$26,607$321,517-$32,447$208,955
Depreciation & amortization——$0$0$105$313$907$907
Stock-based compensation$7,303$15,161$23,673$0$0$18,107$18,771$0

Free plan shows the latest 8 periods; Pro shows all 22 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.